(Q34707909)

4 August 2017

1 reference

title

Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials (English)

1 reference

4 August 2017

1 reference

Kristian Wahlbeck

2

0 references

author name string

Arja Tuunainen

series ordinal

1

1 reference

4 August 2017

Simon Gilbody

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

4 August 2017

published in

Schizophrenia Research

1 reference

4 August 2017

volume

56

1 reference

4 August 2017

issue

1-2

1 reference

4 August 2017

page(s)

1-10

1 reference

Negative symptoms in schizophrenia. Definition and reliability

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Treatment-resistant schizophrenia: clinical experience with new antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

The number needed to treat: a clinically useful measure of treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

The existence of publication bias and risk factors for its occurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Bias in location and selection of studies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Using numerical results from systematic reviews in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

New antipsychotic medications: strategies for evaluation and selected findings

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Newer atypical antipsychotic medication versus clozapine for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

The new antipsychotics, and their potential for early intervention in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900212-2

7 January 2021

10.1016/S0920-9964(01)00212-2

Identifiers

DOI

1 reference

4 August 2017

1 reference